Last Updated: August 8, 2026

PAZOPANIB Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


DrugPatentWatch® Litigation and Generic Entry Outlook for Pazopanib

A generic version of PAZOPANIB was approved as pazopanib hydrochloride by APOTEX on October 19th, 2023.

  Start Trial

AI Deep Research
Ask!
Questions you can ask:
  • What is the 5 year forecast for PAZOPANIB?
  • What are the global sales for PAZOPANIB?
  • What is Average Wholesale Price for PAZOPANIB?
Summary for PAZOPANIB
US Patents:0
Applicants:6
NDAs:6
Drug Prices: Drug price information for PAZOPANIB
DailyMed Link:PAZOPANIB at DailyMed
Drug patent expirations by year for PAZOPANIB
Drug Prices for PAZOPANIB

See drug prices for PAZOPANIB

US Patents and Regulatory Information for PAZOPANIB

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex PAZOPANIB HYDROCHLORIDE pazopanib hydrochloride TABLET;ORAL 217713-001 Oct 19, 2023 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Sun Pharm PAZOPANIB HYDROCHLORIDE pazopanib hydrochloride TABLET;ORAL 215837-001 Oct 19, 2023 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Eugia Pharma PAZOPANIB HYDROCHLORIDE pazopanib hydrochloride TABLET;ORAL 219034-001 Dec 4, 2024 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Novugen PAZOPANIB HYDROCHLORIDE pazopanib hydrochloride TABLET;ORAL 218231-001 Apr 23, 2024 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Torrent PAZOPANIB HYDROCHLORIDE pazopanib hydrochloride TABLET;ORAL 219922-001 Sep 4, 2025 RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Teva Pharms Inc PAZOPANIB HYDROCHLORIDE pazopanib hydrochloride TABLET;ORAL 217517-001 Oct 19, 2023 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

DrugChatter Q&A for PAZOPANIB
Pazopanib fda approval date?
Pazopanib votrient fda approval date?
Pazopanib patent expiry date?
How does pazopanib treat renal cancer?

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links